JNJ
+$0
25,255 sh
REED JOHN C
EVP, Innovative Medicine, R&D, EVP, Pharmaceuticals R&D, Director · SEC CIK 1181561Advertisement
Buy track record
How this insider's open-market purchases have performed100%
of buys now in profit
1 up · 0 down
Avg return since buy+40.8%
Median return+40.8%
Best trade+40.8%
Worst trade+40.8%
Buys scored1
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
+0.0%
0% won · 1 trade
After 3 months
+0.0%
0% won · 1 trade
After 6 months
+0.0%
0% won · 1 trade
After 12 months
+0.0%
0% won · 1 trade
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2008 | RPRX | $7 | $162.5K | NEW | +0.0% | +0.0% | +0.0% | +0.0% | +40.8% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 1 scored trade, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$162.5K
1 trades
Open-market sells
$20.82M
9 trades
Net flow
−$20.66M
Net selling
Total filings
28
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstJNJ
−$2.53M
11,002 sh @ $230
JNJ
+$3.43M
21,721 sh @ $158
JNJ
−$5.28M
21,721 sh @ $243
JNJ
+$4.67M
29,927 sh @ $156
Advertisement
JNJ
−$7.27M
29,927 sh @ $243
JNJ
−$554.8K
2,283 sh @ $243
JNJ
+$0
1,847 sh
JNJ
−$93.7K
385 sh @ $243
JNJ
−$128.5K
528 sh @ $243
JNJ
+$3.43M
21,721 sh @ $158
JNJ
−$4.19M
21,721 sh @ $193
JNJ
−$3.13M
19,137 sh @ $164
JNJ
+$0
25,255 sh
JNJ
−$1.72M
11,002 sh @ $156
JNJ
−$60.1K
385 sh @ $156
JNJ
+$0
1,350 sh
JNJ
+$0
22,255 sh
JNJ
−$1.59M
10,984 sh @ $145
ISIS
+$25.3K
4,900 sh @ $5
ISIS
−$74.4K
4,900 sh @ $15
ISIS
+$26.4K
5,100 sh @ $5
ISIS
−$77.4K
5,100 sh @ $15
ISIS
+$39.5K
10,000 sh @ $4
ISIS
−$139.9K
10,000 sh @ $14
ISIS
+$81.5K
10,000 sh @ $8
ISIS
−$110.6K
10,000 sh @ $11
RPRX
Reed John C, RPRX's Director, spent $162.5K of their own money on 25,000 shares at $7, opening a brand-new position.
+$162.5K
25,000 sh @ $7
Frequently asked questions
How is REED JOHN C's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from REED JOHN C's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.